The stock of InVitae Corp (NYSE:NVTA) is a huge mover today! The stock decreased 3.65% or $0.32 during the last trading session, hitting $8.44. About 72,878 shares traded hands. InVitae Corp (NYSE:NVTA) has declined 6.12% since March 1, 2016 and is downtrending. It has underperformed by 18.33% the S&P500.
The move comes after 9 months negative chart setup for the $284.33M company. It was reported on Oct, 4 by Barchart.com. We have $7.51 PT which if reached, will make NYSE:NVTA worth $31.28M less.
Analysts await InVitae Corp (NYSE:NVTA) to report earnings on November, 3. They expect $-0.65 EPS, up 8.45% or $0.06 from last year’s $-0.71 per share. After $-0.77 actual EPS reported by InVitae Corp for the previous quarter, Wall Street now forecasts -15.58% EPS growth.
InVitae Corp (NYSE:NVTA) Ratings Coverage
Out of 3 analysts covering Invitae (NYSE:NVTA), 1 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 33% are positive. Invitae has been the topic of 3 analyst reports since August 14, 2015 according to StockzIntelligence Inc. JP Morgan maintained the shares of NVTA in a report on Tuesday, August 9 with “Overweight” rating. The stock of InVitae Corp (NYSE:NVTA) earned “Mkt Perform” rating by William Blair on Friday, August 14. The stock of InVitae Corp (NYSE:NVTA) has “Mkt Perform” rating given on Thursday, January 28 by Leerink Swann.
According to Zacks Investment Research, “Invitae Corporation is engaged in genetic diagnostics for hereditary disorders which include breast, colon and pancreatic cancer. It operates primarily in the United States, Israel and internationally. Invitae Corporation is headquartered in San Francisco, California.”
More notable recent InVitae Corp (NYSE:NVTA) news were published by: Bizjournals.com which released: “EXCLUSIVE: DNA testing giant leases entire Potrero Hill redevelopment site” on September 22, 2015, also Seekingalpha.com with their article: “Invitae Corporation: Moving To Equity Dilution Or Insolvency” published on October 23, 2015, Streetinsider.com published: “InVitae (NVTA) Announces Final CMS Pricing for Hereditary Breast Cancer …” on October 03, 2016. More interesting news about InVitae Corp (NYSE:NVTA) were released by: Bizjournals.com and their article: “Genetic testing firm Invitae seeks IPO of $86 million (Video)” published on January 10, 2015 as well as Zacks.com‘s news article titled: “Can the Rally in Invitae (NVTA) Shares Continue?” with publication date: March 31, 2016.
NVTA Company Profile
Invitae Corporation (Invitae), incorporated on January 13, 2010, utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. The Company’s laboratory is located in San Francisco, California. The Company’s product is an assay of over 600 genes that can be used for multiple indications. The test includes multiple genes associated with hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.